This abstract looks very current and looks like it covers the issue, but alas I can not access them without a subscribing library and would need the tutorial version anyway. I am an interested investor, but do not have enough medical background.
ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10960673&dopt=Abstract
TANOX was mentioned on CNBC 9/14/00 AM, as killing two monkey during the clinical trial of E25. Tanox apparently IPO-ed in April, Symbol TNOX. There is no Yahoo BB as yet, that I can find.
Some information I have collected:
Tanox (TNOX)
Anti-IgE antibody for allergic asthma and rhinitis (Xolair)
- excellent Phase III results published
- FDA approval expected to come by the end of the year
- partners Genentech and Novartis
- expected revenue $1.9 billion by 2005; according to R. Stephens.
Phase III data
docguide.com
New study (published August 31) claiming that Xolair will revolutionize how asthma is treated
dailynews.yahoo.com
cnetinvestor.com
cnbc.com
5. Tanox Inc. {TNOX}
The drug development company has been working on a product called E25 for
hay fever and allergies. During the clinical tests, two test monkeys died. The
company explains the two test animals, among 10, were too young and overly
sensitive to the drug. The company is partnered with Genentech Inc. {DNA}
which has announced it will go forward with drug testing.
Re. DNA/Tanox. Apparently it has been missed by the press that the drug killing those monkeys was E26, a
potential follow-up to E25! So, yes, because the two are related, this causes some concern for E25 itself. Also,
the killer dose was some 25X higher than the therapeutic dose used for E25, allowing, of course, for the fact
that the two molecules are different. The cause of death was thrombocytopenia or low platelet count. DNA did
see some transient cases of this during trials of E25 itself. Either way the BLA was filed 2 weeks ago and DNA
is doing now is putting on-hold enrollment of *new* patients in an ongoing phase IIIb study (which presumably
is not part of the extant BLA?).
This is reported to come from Lehman and SSB reports. Although one would expect those two to be DNA apologists given their "Strong Buy" ratings, I would not think they would lie about details such as above. |
